MedX Health Corp. provides update on the release of its Annual Financial Statements and related Disclosures for fiscal 2019 and postponement of release of its First Quarter 2020 Interim Financial Statements and related Disclosures

On May 27, 2020 MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) reported an update on the filing of its Annual Financial Statements and related Disclosures (the "Annual Disclosures") for the year ended December 31, 2019, following the earlier announcement in its Press Release dated April 28, 2020, that filing of the Annual Disclosures would be delayed due to COVID-19 related delays (Press release, MedX Health, MAY 27, 2020, View Source [SID1234558579]). The Company is continuing to work diligently and expeditiously with its auditors, and anticipates that the Annual Disclosures will be filed by June 12, 2020, as previously indicated.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company further announces that filing of the Interim Financial Statements and related Disclosures for the three-month period ended March 31, 2020, the First Quarter of fiscal 2020 (the "Interim Disclosures") will also be delayed owing to COVID-19 related issues. The Company anticipates that the Interim Disclosures will be filed by July 13, 2020.

In relation to the delay in filing of the Annual Disclosures and the Interim Disclosures, MedX relies on the provisions of Ontario Instrument 51-502, Temporary Exemption from Certain Corporate Finance Requirements and corresponding Instruments in the other jurisdictions in which the Company is a reporting issuer.

MedX confirms that there have been no material business developments other than as disclosed in its Press Releases and previous filings, and further confirms that Management and other insiders of the Company have been, since April 28, 2020, and continue to be subject to a trading black-out policy that reflects the principles in section 9 of National Policy 11-207, Failure to-File Cease Trade Orders and Revocations in Multiple Jurisdictions, which will remain in effect until both the Annual Disclosures and the Interim Disclosures have been filed.